J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Post JB
Right arrow Articles by Frishman, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Post JB, , 4th
Right arrow Articles by Frishman, W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies

Post JB 4th and WH Frishman

Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, the drug causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Its pharmaco-dynamics are reviewed in this article, along with the clinical experiences in patients with hypertensive urgencies and emergencies. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam influsion.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
K. S. Lewis
Pharmacological Review of Postoperative Hypertension
Journal of Pharmacy Practice, April 1, 2002; 15(2): 135 - 146.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. A. Felder, H. Sanada, J. Xu, P.-Y. Yu, Z. Wang, H. Watanabe, L. D. Asico, W. Wang, S. Zheng, I. Yamaguchi, et al.
G protein-coupled receptor kinase 4 gene variants in human essential hypertension
PNAS, March 19, 2002; 99(6): 3872 - 3877.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
R. C. Prielipp, M. H. Wall, L. Groban, J. R. Tobin, F. H. Fahey, B. A. Harkness, D. A. Stump, R. L. James, M. A. Cannon, J. Bennett, et al.
Reduced Regional and Global Cerebral Blood Flow During Fenoldopam-Induced Hypotension in Volunteers
Anesth. Analg., July 1, 2001; 93(1): 45 - 52.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Clinical Pharmacology